Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Teriflunomide tablets.
Share price of Glenmark Pharma rose 1.5 percent in the early trade on Friday after company received a USFDA approval for Teriflunomide tablets.
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Teriflunomide tablets, 7 mg and 14 mg, a generic version of Aubagio tablets, 7 mg and 14 mg, of Sanofi-Aventis US, LLC.
With this approval, Glenmark is eligible for 180 days of shared generic drug exclusivity for Teriflunomide Tablets, 7 mg and 14 mg.
Company's current portfolio consists of 142 products authorized for distribution in the US marketplace and 57 ANDA’s pending approval with the US FDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, company said in release.
At 09:18 hrs Glenmark Pharma was quoting at Rs 671.70, up Rs 7.25, or 1.09 percent on the BSE.
For more market news, click here
